These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6756155)

  • 1. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine.
    Lass JH; Lazarus HM; Reed MD; Herzig RH
    Am J Ophthalmol; 1982 Nov; 94(5):617-21. PubMed ID: 6756155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis.
    Lazarus HM; Hartnett ME; Reed MD; Murphy BF; Lass JH
    Am J Ophthalmol; 1987 Nov; 104(5):476-80. PubMed ID: 3314526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corneal toxicity with systemic cytarabine.
    Hopen G; Mondino BJ; Johnson BL; Chervenick PA
    Am J Ophthalmol; 1981 Apr; 91(4):500-4. PubMed ID: 6939330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An in vitro method which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agents.
    Lazarus HM; Imperia PS; Botti RE; Mack RJ; Lass JH
    Lens Eye Toxic Res; 1989; 6(1-2):59-85. PubMed ID: 2488034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
    Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
    Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation.
    Mori T; Watanabe M; Kurotori-Sotome T; Ito C; Yamada K; Yashima T; Kobayashi N; Kondo S; Aisa Y; Kato J; Ogawa Y; Tsubota K; Shigematsu N; Kubo A; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2008 Aug; 42(3):197-9. PubMed ID: 18500372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system toxicity of high-dose systemic cytosine arabinoside.
    Lazarus HM; Herzig RH; Herzig GP; Phillips GL; Roessmann U; Fishman DJ
    Cancer; 1981 Dec; 48(12):2577-82. PubMed ID: 7306918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular toxicity from high-dose cytosine arabinoside.
    Ritch PS; Hansen RM; Heuer DK
    Cancer; 1983 Feb; 51(3):430-2. PubMed ID: 6571799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients.
    Özcan G; Uçakhan ÖÖ
    Turk J Ophthalmol; 2021 Apr; 51(2):114-117. PubMed ID: 33951900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results.
    Wolff SN; Herzig RH; Fay JW; Phillips GL; Lazarus HM; Flexner JM; Stein RS; Greer JP; Cooper B; Herzig GP
    J Clin Oncol; 1989 Sep; 7(9):1260-7. PubMed ID: 2769327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
    Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
    Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
    Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study.
    Mantovani L; Hasenclever D; Krahl R; Pönisch W; Herold M; Pasold R; Fiedler F; Dölken G; Kämpfe D; Schmoll HJ; Súbert R; Kubel M; Niederwieser D; Helbig W;
    Leuk Lymphoma; 2002 Feb; 43(2):265-74. PubMed ID: 11999557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.
    Lee EJ; George SL; Caligiuri M; Szatrowski TP; Powell BL; Lemke S; Dodge RK; Smith R; Baer M; Schiffer CA
    J Clin Oncol; 1999 Sep; 17(9):2831-9. PubMed ID: 10561359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
    Matulonis UA; Birrer MJ; O'Malley DM; Moore KN; Konner J; Gilbert L; Martin LP; Bauer TM; Oza AM; Malek K; Pinkas J; Kim SK
    Clin Cancer Res; 2019 Mar; 25(6):1727-1736. PubMed ID: 30413525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Handling punctate keratitis resulting from systemic cytarabine.
    Friedland S; Loya N; Shapiro A
    Ann Ophthalmol; 1993 Aug; 25(8):290-1. PubMed ID: 8239322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
    Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
    Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
    Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
    N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
    Mayer RJ; Davis RB; Schiffer CA; Berg DT; Powell BL; Schulman P; Omura GA; Moore JO; McIntyre OR; Frei E
    N Engl J Med; 1994 Oct; 331(14):896-903. PubMed ID: 8078551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.